Cannara Biotech Inc. (V:LOVE*CA)

Business Focus: Medical Farming

Sector:  Healthcare Industry:  Healthcare Facilities & Services
 
Company Contact
Address: Suite 2050 - 1055, West Georgia Street
VANCOUVER BC V6E 3P3
Tel: 1-514-5434200
Website: https://www.cannara.ca/en
IR: See website
<
Key People
Zohar Krivorot
Chairman of the Board, Chief Executive Officer
Nicholas Sosiak
Chief Financial Officer
Avi Krivorot
Chief Technology Officer
Noemi Follain
Vice President - Finance
Anthony Manouk
Vice President - Compliance, General Manager
 
Business Overview
Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Company's brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis.
Financial Overview
For the three months ended 30 November 2023, Cannara Biotech Inc revenues increased 89% to C$19.5M. Net income increased from C$3K to C$2.1M. Revenues reflect Cannabis operations segment increase of 97% to C$18.6M, Real estate operations segment increase of 5% to C$909K. Net income benefited from Cannabis operations segment income increase from C$1.2M to C$3.3M, Real estate operations segment income increase of 7% to C$837K.
Reporting Currency: Canadian Dollars
Enterprise value: $123.43M as of Nov 30, 2023
Annual revenue (TTM): $66.73M as of Nov 30, 2023
EBITDA (TTM): -$5.13M as of Nov 30, 2023
Net annual income (TTM): $9.05M as of Nov 30, 2023
Free cash flow (TTM): -$2.28M as of Nov 30, 2023
Net Debt Last Fiscal Year: $46.02M as of Nov 30, 2023
Shares outstanding: 90,018,952 as of Dec 12, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.